Bank of New York Mellon Corp Purchases Shares of 1,015,182 Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Bank of New York Mellon purchased 1,015,182 Amneal Pharmaceuticals shares worth approximately $17.6 million, giving it a 0.32% stake. Institutional investors collectively own 31.82% of the company.
• Amneal insiders sold 413,016 shares worth about $7.2 million during the latest quarter, including substantial sales by two executive vice presidents.
• Analyst sentiment remains positive, with the stock carrying a consensus “Buy” rating and a $19.00 price target. Amneal also beat quarterly earnings estimates, reporting $0.30 per share versus the expected $0.24.

Bank of New York Mellon Corp purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,015,182 shares of the company's stock, valued at approximately $17,573,000. Bank of New York Mellon Corp owned about 0.32% of Amneal Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $26,000. Federated Hermes Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company's stock valued at $29,000 after buying an additional 2,168 shares in the last quarter. Comerica Bank grew its position in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company's stock valued at $30,000 after buying an additional 1,957 shares during the last quarter. Transamerica Financial Advisors LLC grew its position in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company's stock valued at $37,000 after buying an additional 2,460 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter worth $42,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the transaction, the executive vice president owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This represents a 36.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AMRX. Zacks Research raised Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Friday, August 7th. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Barclays raised their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 20th. The Goldman Sachs Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Finally, Weiss Ratings raised Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $19.00.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $17.47 on Tuesday. The stock's 50-day moving average price is $17.71 and its 200 day moving average price is $14.88. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The stock has a market capitalization of $5.58 billion, a PE ratio of 35.65 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.32 and a 52-week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source